Pharmacoeconomic analysis of various treatment regimens of Congo-Crimean hemorrhagic fever

International Journal of Infectious Diseases, 2020

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.1016/j.ijid.2020.09.1367
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Background: Kazakhstan has gained experience in the treatment of Congo-Crimean hemorrhagic fever (CCHF) with ribavirin and immunized plasma. In recent years, the effectiveness of therapy in various diseases has been evaluated not only by clinical and laboratory parameters, but also by pharmacoeconomic indicators.